http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013112675-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8672dbc019ff192d2e20697055921d28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
filingDate 2011-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dda68edac39fde0d26dc783ee452f5c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9101e83fbe69bdad289ae589355500c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc654b6bd9e9fc94953cc371c292a51a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b328bc08e7bd5b5c9b1761ae2771696d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8de9076006fd1ae2520751ccfc0f92eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_108c21d8e0d5993c0e913b320dbbff8b
publicationDate 2013-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2013112675-A
titleOfInvention Stabilized candesartan-containing drug composition
abstract It has been known that candesartan cilexetil preparations lose the stability of active ingredients due to the collapse of the three-dimensional structure of crystals during the manufacturing process such as tableting. A decrease in the stability of the active ingredient causes generation of related substances, leading to a decrease in the content of the active ingredient. For this reason, there is a concern that a stable therapeutic effect cannot be obtained after long-term storage. Therefore, stabilization of the active ingredient in the candesartan cilexetil formulation has been demanded. [Solution] By containing a lower alcohol in the candesartan cilexetil preparation, a drug composition having excellent storage stability and stable active ingredient content over a long period of time can be provided. Thereby, the above-mentioned problem is solved. [Selection figure] None
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5844929-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112957336-A
priorityDate 2011-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2541
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426106964
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2540
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414855894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665634
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535070
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452788844
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6436605
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416290180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702

Total number of triples: 37.